Medigen Vaccine Biologics (6547) - Total Liabilities
Based on the latest financial reports, Medigen Vaccine Biologics (6547) has total liabilities worth NT$454.64 Million TWD (≈ $14.32 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Medigen Vaccine Biologics - Total Liabilities Trend (2012–2025)
This chart illustrates how Medigen Vaccine Biologics's total liabilities have evolved over time, based on quarterly financial data. See 6547 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Medigen Vaccine Biologics Competitors by Total Liabilities
The table below lists competitors of Medigen Vaccine Biologics ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
INPAQ Technology Co Ltd
TWO:6284
|
Taiwan | NT$6.22 Billion |
|
Shanghai Shentong Metro Co Ltd
SHG:600834
|
China | CN¥276.36 Million |
|
Aduro Clean Technologies Inc. Common Stock
NASDAQ:ADUR
|
USA | $8.46 Million |
|
Importadora y Exportadora de la Patagonia SA
BA:PATA
|
Argentina | AR$528.04 Billion |
|
Huatian Hotel Group Co Ltd
SHE:000428
|
China | CN¥3.65 Billion |
|
Aberdeen Standard Global Infrastructure Income Fund
NYSE:ASGI
|
USA | $4.35 Million |
|
GS P&L CO LTD
KO:499790
|
Korea | ₩1.17 Trillion |
|
Baotou Dongbao Bio-Tech Co Ltd
SHE:300239
|
China | CN¥831.08 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Medigen Vaccine Biologics's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Medigen Vaccine Biologics.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Medigen Vaccine Biologics's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Medigen Vaccine Biologics (2012–2025)
The table below shows the annual total liabilities of Medigen Vaccine Biologics from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$454.64 Million ≈ $14.32 Million |
-11.53% |
| 2024-12-31 | NT$513.92 Million ≈ $16.19 Million |
-77.12% |
| 2023-12-31 | NT$2.25 Billion ≈ $70.76 Million |
-3.13% |
| 2022-12-31 | NT$2.32 Billion ≈ $73.05 Million |
+272.21% |
| 2021-12-31 | NT$622.95 Million ≈ $19.63 Million |
+78.29% |
| 2020-12-31 | NT$349.40 Million ≈ $11.01 Million |
-61.62% |
| 2019-12-31 | NT$910.28 Million ≈ $28.68 Million |
+59.39% |
| 2018-12-31 | NT$571.10 Million ≈ $17.99 Million |
-7.20% |
| 2017-12-31 | NT$615.41 Million ≈ $19.39 Million |
+76.89% |
| 2016-12-31 | NT$347.90 Million ≈ $10.96 Million |
+12.52% |
| 2015-12-31 | NT$309.19 Million ≈ $9.74 Million |
+127.43% |
| 2014-12-31 | NT$135.95 Million ≈ $4.28 Million |
+598.49% |
| 2013-12-31 | NT$19.46 Million ≈ $613.19K |
-12.13% |
| 2012-12-31 | NT$22.15 Million ≈ $697.85K |
-- |
About Medigen Vaccine Biologics
Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for th… Read more